Versa Vascular Appoints Bill Shields as CEO

August 14, 2026—Versa Vascular, Inc. announced the appointment of Bill Shields as Chief Executive Officer. Former Versa CEO David Hovda is retiring. He will remain an advisor to the company.

Versa stated it is developing a transcatheter tricuspid repair therapy for patients and anatomies that have historically lacked viable options.

According to the company, Shield served with Medtronic’s structural heart franchise for the last 15 years. Most recently, he was Vice President and General Manager of its Transcatheter Mitral and Tricuspid Therapies division, leading product development and multiple clinical studies for 7 years. Previously, he led upstream and downstream marketing for the company’s transcatheter valve programs.

Earlier, Shields was a senior engineer with Stryker. He received a bachelor’s degree in mechanical engineering from Dartmouth College and an MBA from Northwestern University’s Kellogg School of Management.

Additionally, Versa Vascular announced a $15 million expansion to its Series C, bringing the total committed capital for the round to $42 million.

The company advised that the additional funding will support completion of the company’s first-in-human clinical study of its AdapTR transcatheter tricuspid repair device outside of the United States; the United States early feasibility study of the technology; and further product development and optimization.

“I am thrilled to join Versa Vascular at a time when we are seeing positive results clinically, close to expanding our clinical work to the United States, and receiving continued investor confidence,” commented Shields in the company’s press release.

Shields continued, “I have seen and launched a number of innovative transcatheter devices in my career, and the AdapTR technology shows similar promise to create a superior therapy for patients. I want to thank David Hovda and the team for their commitment to product development and refinement that has led to a truly novel solution that is showing it can have a positive impact on patients’ lives.”